Biblio

Author Title [ Type(Desc)] Year
Filters: Author is Jamani, Kareem  [Clear All Filters]
Journal Article
Beland B, Hahn C, Jamani K, Chhibber S, White C, Atkins H, Storek J. Autologous Hematopoietic Stem Cell Transplant for the Treatment of Refractory Myasthenia Gravis with Anti-Muscle Specific Kinase Antibodies. Muscle Nerve. 2022.
Cheng G-S, Bondeelle L, Gooley T, He Q, Jamani K, Krakow EF, Flowers MED, de Latour RPeffault, Michonneau D, Socié G, et al. Azithromycin use and increased cancer risk among patients with bronchiolitis obliterans after hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2019.
Kim DDong Hwan, Popradi G, Lepic K, Paulson K, Allan D, Nampoothiri RVasudevan, Lachance S, Deotare U, White J, Elemary M, et al. Cell Therapy Transplant Canada (CTTC) Consensus-Based Guideline 2024 for Management and Treatment of Chronic Graft-Versus-Host Disease and Future Directions for Development. Curr Oncol. 2024;31(3):1426-1444.
Woo MMK, Levin D, Li DY, David J, Buresi M, Gupta M, Nasser Y, Andrews CN, Durand C, Osman MS, et al. Esophageal motility in systemic sclerosis before and after autologous hematopoietic cell transplantation. Clin Rheumatol. 2023.
Murray A, Linn SMar, Yu B, Novitzky-Basso I, Mattsson J, Kennah M, Elemary M, White J, Lemieux C, Jamani K, et al. Real-world experience with ruxolitinib therapy for steroid-refractory acute graft versus host disease. Bone Marrow Transplant. 2024.
Kinzel M, Dowhan M, Kalra A, Williamson TS, Dabas R, Jamani K, Chaudhry A, Shafey M, Jimenez-Zepeda V, Duggan P, et al. Risk factors for the incidence of PTLD and the mortality due to PTLD after hematopoietic cell transplantation. Transplant Cell Ther. 2021.
Taylor M, Cole SW, Strom J, Brazauskas R, K Baker S, Phelan R, Buchbinder DK, Hamilton BK, Schoemans HM, Shaw BE, et al. Unfavorable transcriptome profiles and social disadvantage in hematopoietic cell transplantation: a CIBMTR analysis. Blood Adv. 2023.